3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Gastrointestinal
1
Conditions
Neurofibromatosis 1
5
Carcinoma, Non-Small-Cell Lung
3
Pancreatic Neoplasms
2
Neurofibroma, Plexiform
2
Triple Negative Breast Neoplasms
1
Sarcoma, Kaposi
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pain
1
Optic Nerve Glioma
1
Neurofibrosarcoma
1
Neoplasms
1
Lung Neoplasms
1
Liver Neoplasms
1
Gastrointestinal Neoplasms
1
Colorectal Neoplasms
1
Carcinoma, Hepatocellular
1
Astrocytoma
1
Acquired Immunodeficiency Syndrome
1
AIDS-related Kaposi sarcoma
1
Interventions
Fluorouracil
8
Oxaliplatin
7
Leucovorin
6
Irinotecan
6
Gemcitabine
5
fludarabine
3
aldesleukin
3
Pemetrexed
3
Nivolumab
3
Cyclophosphamide
3
Cetuximab
3
Capecitabine
3
5,10-methylenetetrahydrofolic acid
3
dehydroftorafur
2
cobimetinib
2
Specimen Handling
2
Panitumumab
2
Interleukin-2
2
Docetaxel
2
Bevacizumab
2
130-nm albumin-bound paclitaxel
2
tivozanib
1
sodium propionate
1
rucaparib
1
rilotumumab
1
repotrectinib
1
regorafenib
1
pralsetinib
1
pertuzumab
1
pembrolizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Gastrointestinal Neoplasms
×
AZD 6244
×
Clear all
NCT02450656
2018-08-27
M14AFS
The Netherlands Cancer Institute
Phase 1/2
Unknown
320 enrolled